Scholars Central

Conference abstract

Validated LC-MS method for determination of Tamsulosin in human plasma and its application in bioequivalence study

Authors: Maricela Mart?nez

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

A n accurate, precise, and sensitive high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) assay was developed for the determination of Tamsulosin in human plasma samples to compare the bioavailability of 2 capsules (0.4 mg) oral formulations in 26 volunteers. Tamsulosin concentrations were analyzed by a rapid and selective and validated liquid chromatographic/tandem mass spectrometric method. Following protein-precipitation, the analyte and internal standard (metoprolol) were separated from human plasma using a gradient mobile phase on an Acquity ? UPLC BEH C18 column. A TQD Waters tandem mass spectrometer equipped with IonSpray ionization source was used as detector and was operated in the positive ion mode. Multiple reaction monitoring using the precursor to product ion combinations of m/z 409.10>228.02 and m/z 268.10>72.05was performed to quantify Tamsulosin and internal standard, respectively. Th e method was linear in the concentration range of 0.40 ? 28.00 ng/mL using 500 μL of plasma. Th e lower limit of quantifi cation was 0.40 ng/mL. Th e intra- and inter-day relative standard deviation over the entire concentration range was less than 2.24%. Accuracy determined at three concentrations (1.20, 14.20, and 24.80 ng/mL for Tamsulosin) ranged from 1.03% to 4.59% in terms of relative error. Each plasma sample was chromatographed within 3.2 minutes. Th e bioequivalence study was an open- label randomized 2-period crossover trial with a 1-week washout period. Plasma samples were obtained over a 32-hour period. Th e bioequivalence between the two formulations was assessed by calculating individual peak plasma concentrations (C max ) and area under the curve (AUC 0-32h ) ratios (test/reference). Th e statistical interval proposed was 80-125%, as established by international regulatory agencies

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Bioequivalence & Bioavailability.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioequivalence & Bioavailability
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Maricela Mart?nez”